Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery

Abstract

Background

The significance of surgical resection in pancreatic ductal adenocarcinoma (PDAC) with positive peritoneal cytology (PPC) is controversial. This study aimed to evaluate whether preceding chemotherapy could be beneficial for patients with PDAC with PPC.

Methods

Between 2017 and 2019, 34 consecutive PDAC patients diagnosed with PPC without distant metastasis were retrospectively reviewed. Twenty-three patients did not receive neoadjuvant treatment (NAT) and 11 received NAT. All patients received systemic chemotherapy after PPC was confirmed, and they underwent surgical resection if PPC turned negative. The treatment course, ratio of conversion surgery (CS), and prognosis were evaluated. Moreover, the prognosis of PPC patients who underwent up-front surgery without NAT between 2003 and 2016 was analyzed as a comparative cohort.

Results

The median survival time (MST) of the patients without NAT was 31.4 months. CS was performed in 52.2% of the patients. Patients who underwent CS had better prognoses than those who did not undergo CS (p = 0.005). The CS rate was significantly higher in resectable PDAC (78.5%) than in borderline/unresectable PDAC (11.1%) (p = 0.002). The prognosis of patients with resectable PDAC was improved with preceding chemotherapy compared with up-front surgery (MST 13.0 months; p = 0.016). After NAT, the CS rate was low (27.3%), and the MST was only 14.1 months.

Conclusions

As an initial treatment for PDAC patients with PPC, chemotherapy may lead to a favorable prognosis. Especially, resectable PDAC is associated with a greater chance of improved prognosis. Future studies are required to ascertain whether up-front surgery or preceding chemotherapy should be performed for these patients.

This is a preview of subscription content, access via your institution.

Fig. 1.
Fig. 2.
Fig. 3.

References

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

    Article  Google Scholar 

  2. 2.

    Cancer Registry and Statistics. Cancer Information Service NCC, Japan. (2020). https://ganjoho.jp/reg_stat/statistics/dl/index.html. Accessed 1 Nov 2020.

  3. 3.

    Tanaka M, Mihaljevic AL, Probst P, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106:1590–601.

    CAS  Article  Google Scholar 

  4. 4.

    Ariake K, Motoi F, Ohtsuka H, et al. Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention. Surg Today. 2017;47:1434–42.

    Article  Google Scholar 

  5. 5.

    Ariake K, Motoi F, Shimomura H, et al. 18-Fluorodeoxyglucose positron emission tomography predicts recurrence in resected pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2018;22:279–87.

    Article  Google Scholar 

  6. 6.

    American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th edn. Chicago: Springer; 2017.

    Google Scholar 

  7. 7.

    Brierley JD, Gospodarowicz MK, Wittekind C. Union for international cancer control. TNM classification of malignant tumours. 8th edn. Oxford: Wiley Blackwell; 2017.

    Google Scholar 

  8. 8.

    Japan Pancreas Society. Classification of . English. Tokyo: Kanehara and Co., Ltd; 2017.

    Google Scholar 

  9. 9.

    Satoi S, Murakami Y, Motoi F, et al. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. J Gastrointest Surg. 2015;19:6–14; discussion 14.

  10. 10.

    Tsuchida H, Fujii T, Mizuma M, et al. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: a nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery. 2019;166:997–1003.

    Article  Google Scholar 

  11. 11.

    Cao F, Li J, Li A, Li F. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Oncotarget. 2017;8:15004–13.

    Article  Google Scholar 

  12. 12.

    Yin Z, Ma T, Chen S. Intraoperative peritoneal washing cytology on survival in pancreatic ductal adenocarcinoma with resectable, locally advanced, and metastatic disease. Pancreas. 2019;48:519–25.

    Article  Google Scholar 

  13. 13.

    National Comprehensive Cancer Network. NCCN practice guidelines for pancreatic cancer, Version 1. (2020). https://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf. Accessed 1 Nov 2020.

  14. 14.

    Yamada S, Fujii T, Kanda M, et al. Value of peritoneal cytology in potentially resectable pancreatic cancer. Br J Surg. 2013;100:1791–6.

    CAS  Article  Google Scholar 

  15. 15.

    Oh SY, Edwards A, Mandelson MT, et al. Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience. Am J Surg. 2017;213:94–9.

    Article  Google Scholar 

  16. 16.

    Satoi S, Yamaue H, Kato K, et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2013;20:590–600.

    Article  Google Scholar 

  17. 17.

    Ariake K, Motoi F, Mizuma M, et al. Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report. Surg Case Rep. 2017;3:15.

    Article  Google Scholar 

  18. 18.

    Satoi S, Fujii T, Yanagimoto H, et al. Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg. 2017;265:397–401.

    Article  Google Scholar 

  19. 19.

    Satoi S, Yanagimoto H, Yamamoto T, et al. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution. J Hepatobiliary Pancreat Sci. 2017;24:289–96.

    Article  Google Scholar 

  20. 20.

    Mitachi K, Ariake K, Motoi F, Unno M. Conversion surgery for positive peritoneal washing cytology in pancreatic cancer. BMJ Case Rep. 2019;12:e229993.

    Article  Google Scholar 

  21. 21.

    Takadate T, Morikawa T, Ishida M, et al. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Surg Today. 2020. https://doi.org/10.1007/s00595-020-02121-4.

    Article  PubMed  Google Scholar 

  22. 22.

    Yoshioka R, Saiura A, Koga R, et al. The implications of positive peritoneal lavage cytology in potentially resectable pancreatic cancer. World J Surg. 2012;36:2187–91.

    Article  Google Scholar 

  23. 23.

    Yachida S, Fukushima N, Sakamoto M, Matsuno Y, Kosuge T, Hirohashi S. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg. 2002;89:573–8.

    CAS  Article  Google Scholar 

  24. 24.

    Abe T, Ohuchida K, Endo S, et al. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Surgery. 2017;161:951–8.

    Article  Google Scholar 

  25. 25.

    Aoki S, Mizuma M, Hayashi H, et al. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Pancreatology. 2020. https://doi.org/10.1016/j.pan.2020.08.022.

    Article  PubMed  Google Scholar 

  26. 26.

    Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.

    CAS  Article  Google Scholar 

  27. 27.

    Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406.

    CAS  Article  Google Scholar 

  28. 28.

    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

    CAS  Article  Google Scholar 

  29. 29.

    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.

    Article  Google Scholar 

Download references

Acknowledgment

This study was supported by a Grant from the Pancreas Research Foundation of Japan.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kyohei Ariake MD.

Ethics declarations

Disclosure

Fuyuhiko Motoi—received research funding from Taiho pharm and Chugai Pharm. Michiaki Unno—Taiho, Takeda, Chugai, Yakult, Asahi Kasei.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 1751 KB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ariake, K., Mizuma, M., Motoi, F. et al. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery. Ann Surg Oncol (2021). https://doi.org/10.1245/s10434-021-09718-0

Download citation